Medication Errors, Drug Packaging On USP's Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Pharmacopeia will hear comments and vote on 12 proposed resolutions at its convention in Washington, D.C. March 9-13. One proposal calls for "further consideration" of drug packaging for increasingly complex ingredients and dosage forms.
You may also be interested in...
Biovail Tramadol Approval Awaits New Trade Name
FDA "approvable" letter for the orally disintegrating tablet formulation of the analgesic cites labeling issues, including the product's name. Biovail's extended-release version of tramadol is approvable under the brand Ralivia ER.
Janssen To Change Name Of Reminyl Products
Janssen agreed to change the brand name for galantamine products due to continued confusion with Aventis' Amaryl, which has resulted in medication errors. The company will submit new proposed names to FDA for review.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.